Optinose is a company based in Oslo, Norway, specializing in innovative nasal delivery devices aimed at enhancing drug administration through the intranasal route. The organization focuses on developing advanced technologies for powder delivery and breath-actuated systems, which facilitate effective and efficient medication delivery. Their core expertise includes the design of specialized nosepiece units for various therapeutic applications, including the delivery of oxytocin, thereby addressing unmet medical needs in the field of nasal drug delivery.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 6 2026

74 Patents

#9 in Oslo

#20 in Norway

#10,121 in the World

Oslo, Norway

Optinose as

Forward Citations = 3,456

32 inventors:

Per Gisle Djupesland (71 out of 80 patents)

Colin David Sheldrake (14 out of 19 patents)

Roderick Peter Hafner (12 out of 29 patents)

4. Ramy A Mahmoud (7 out of 11 patents)

5. Michael E Leclerc (6 out of 48 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Optinose as. Retrieved from https://idiyas.com/company/optinose-as

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

8 patents (CIPO):

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

26 patents (EPO):

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]